Phase 3 Study of ASP7374 - Open-label Study of Intramuscular ASP7374 in Adults ≥61 Years of Age
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2017
Price : $35 *
At a glance
- Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary)
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 10 Jan 2017 According to an Astellas Pharma media release, the company will withdraw the application for marketing approval of ASP7374 which the company has filled in Japan as the company has terminated the development agreement with UMN Pharma.
- 15 Jan 2014 Results from this trial were reported by Astellas Pharma and UMN Pharma, according to an UMN Pharma media release.
- 01 Nov 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History